【一周新资讯--肝癌 239】2024 W5301

主要研究结果：

• 回顾性分析了296例HCC，ATSI评分由两个独立预后风险因素发展而来：

• 基线AFP≥400 ng/ml：HR=1.73; P=0.046

• 初始肿瘤形状不规则性：HR=1.94; P=0.041

• 0/1/2分患者的中位OS=未达到/25.8/17.03(P=0.001)，中位PFS=10.83/8.03/5.03(P<0.001)

• 验证集验证了这些结果，0/1/2分：

• 中位OS, 37.43/24.27/14.03个月，P=0.028

• 中位PFS, 13.93/8.30/4.90个月，P<0.001

参考文献：

Zhang F, Wang YS, Li SP, Zhao B, Huang N, Song RP, Meng FZ, Feng ZW, Zhang SY, Song HC, Chen XP, Liu LX, Wang JZ. Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study. J Gastroenterol. 2024 Dec 23. doi: 10.1007/s00535-024-02202-y. Epub ahead of print. PMID: 39714631.